SCHEMBL3565799

SCHEMBL3565799

O=C(N1CC(CCl)c2c1ccc1ccccc21)C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADH1A P07327 2/20 0.46
KIT P10721 2/20 0.46
FLT1 P17948 2/20 0.46
KDR P35968 2/20 0.46
ABL2 P42684 2/20 0.46
FLT4 P35916 1/20 0.46
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 3/20 0.35
MAPT P10636 2/20 0.35
GLA P06280 1/20 0.35
GAA P10253 1/20 0.35
RCE1 Q9Y256 1/20 0.35
POLB P06746 1/20 0.34
HTT P42858 1/20 0.34
HCRTR1 O43613 3/20 0.33
HCRTR2 O43614 3/20 0.33
KDM2B Q8NHM5 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
KCNJ11 Q14654 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3830699 0.85 ADH1A (0.50) ADH1AKITFLT1KDRABL2
SCHEMBL3562423 0.83 ADH1A (0.38) ADH1AKITFLT1KDRABL2
SCHEMBL3564945 0.82 ADH1A (0.44) ADH1AKITFLT1KDRABL2
SCHEMBL3558566 0.82 MAPT (0.38) ADH1AKITFLT1KDRABL2
SCHEMBL16487231 0.82 ADH1A (0.69) ADH1AKITFLT1KDRABL2
SCHEMBL30373903 0.82 ADH1A (0.69) ADH1AKITFLT1KDRABL2
SCHEMBL16487233 0.82 ADH1A (0.69) ADH1AKITFLT1KDRABL2
SCHEMBL3559296 0.81 CA12 (0.37) ADH1AKITFLT1KDRABL2
SCHEMBL3559992 0.81 ADH1A (0.37) ADH1AKITFLT1KDRABL2
SCHEMBL4591116 0.81 ADH1A (0.53) ADH1AKITFLT1KDRABL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718688-B2 Nitrobenzindoles and their use in cancer therapy AUCKLAND UNISERVICES LIMITED (NZ) 2010-05-18 US disclosed
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization AUCKLAND UNISERVICES LIMITED (NZ) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization HIF1AN, HYOU1, HIF1A ADH1A 162/4885KIT 2112/4885FLT1 1014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.